HEALTHCARE RESOURCE UTILIZATION IN PATIENTS RECEIVING PEMBROLIZUMAB OR DOCETAXEL WITH PREVIOUSLY TREATED ADVANCED NSCLC

被引：2
|
作者：
Huang, M. [1 ]
Pellissier, J. [1 ]
Liao, J. [1 ]
机构：
[1] Merck & Co Inc, N Wales, PA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2334
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN258
引用
收藏
页码：A755 / A755
页数：1
相关论文
共 50 条
  • [1] A randomized phase II study of pivanex and docetaxel compared to docetaxel monotherapy in patients with previously treated advanced NSCLC
    Raghunadharao, D
    Koralewski, P
    Serwatowski, P
    Gruszfeld, A
    Lakshmaiah, K
    Szczesna, A
    Savin, M
    Yen, K
    Bhatnagar, A
    Green, M
    [J]. LUNG CANCER, 2005, 49 : S265 - S265
  • [2] Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
    Huang, Min
    Lou, Yanyan
    Pellissier, James
    Burke, Thomas
    Liu, Frank Xiaoqing
    Xu, Ruifeng
    Velcheti, Vamsidhar
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) : 140 - 150
  • [3] Gefitinib versus Docetaxel for Previously Treated NSCLC
    Tassinari, Davide
    Lazzari-Agli, Luigi
    Tombesi, Paola
    Sartori, Sergio
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (13) : 4610 - 4610
  • [4] Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
    Levy, B.
    Giaccone, G.
    Besse, B.
    Felip, E.
    Garassino, M.
    Domine, M.
    Garrido, P.
    Piperdi, B.
    Ponce Aix, S.
    Slepetis, R.
    Wu, X.
    Fandi, A.
    Paz-Ares, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1803 - S1804
  • [5] Determining the Efficacy of Pembrolizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma
    Lin, Timothy A.
    Das, Ananya
    McCaw, Zachary
    Ludmir, Ethan B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16) : 3075 - +
  • [6] A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy
    Wu, L.
    Fang, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S482 - S483
  • [7] KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC
    Ren, Shengxiang
    Feng, Jifeng
    Ma, Shenglin
    Chen, HuaJun
    Ma, Zhiyong
    Huang, Cheng
    Zhang, Li
    He, Jianxing
    Wang, Changli
    Zhou, Jianying
    Danchaivijtr, Pongwut
    Wang, Chin-Chou
    Vynnychenko, Ihor
    Wang, Kai
    Orlandi, Francisco
    Sriuranpong, Virote
    Li, Ben
    Ge, Jun
    Dang, Thao
    Zhou, Caicun
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (03) : 623 - 634
  • [8] Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta -analysis.
    Des Guetz, Gaetan
    Landre, Thierry
    Nicolas, Patrick
    Vergnenegre, Alain
    Chouaid, Christos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Bortezomib ± docetaxel in previously treated patients with advanced nonsmall cell lung cancer (NSCLC):: A phase 2 study.
    Fanucchi, MP
    Fossella, F
    Fidias, P
    Natale, RB
    Belt, RJ
    Carbone, DP
    Govindan, R
    Raez, L
    Robert, F
    Schiller, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 629S - 629S
  • [10] Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC
    Barlesi, F.
    Garon, E.
    Kim, D-W.
    Felip, E.
    Han, J-Y.
    Kim, J-H.
    Ahn, M-J. A.
    Fidler, M. J.
    Gubens, M. A.
    Castro, G.
    Surmont, V.
    Li, Q.
    Deitz, A. C.
    Lubiniecki, G.
    Herbst, R. S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345